thalidomide has been researched along with Osteolysis in 17 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 9.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 5.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "In most cases multiple myeloma is an incurable plasma cell malignancy." | 2.43 | Current treatment options for myeloma. ( Dimopoulos, MA; Rahemtulla, A; Terpos, E, 2005) |
| "Multiple myeloma is the second most common hematologic malignancy, with approximately 15,000 new cases each year in the United States." | 2.41 | Recent advances in multiple myeloma. ( Berenson, JR; Sjak-Shie, NN; Vescio, RA, 2000) |
| "Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow." | 1.46 | A case of multiple myeloma with navicular bone involvement. ( Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E, 2017) |
| "Multiple myeloma is a malignant hematological disorder of the mature B-cell lymphocytes originating in the bone marrow." | 1.43 | Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. ( Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K, 2016) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalantri, SA | 1 |
| Nath, UK | 1 |
| Banerjee, D | 1 |
| Bhattacharyya, M | 1 |
| Yildizhan, E | 1 |
| Kaynar, L | 1 |
| Tiren, N | 1 |
| Canoz, O | 1 |
| Eser, B | 1 |
| Khammar, Z | 1 |
| Ouazzani, M | 1 |
| Bennani, B | 1 |
| Oubelkacem, N | 1 |
| Berrady, R | 1 |
| Kurihara, Y | 1 |
| Nakano, K | 1 |
| Eto, A | 1 |
| Furue, M | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
| Smith, D | 1 |
| Stevens, J | 1 |
| Quinn, J | 1 |
| Cavenagh, J | 1 |
| Ingram, W | 1 |
| Yong, K | 1 |
| Schuelper, N | 1 |
| Flohr, A | 1 |
| Trümper, L | 1 |
| Wulf, GG | 1 |
| Sharman, JP | 1 |
| Chmielecki, J | 1 |
| Morosini, D | 1 |
| Palmer, GA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Stafl, J | 1 |
| Miller, VA | 1 |
| Ali, SM | 1 |
| Ise, M | 1 |
| Tsujimura, H | 1 |
| Sakai, C | 1 |
| Kumagai, K | 1 |
| Schabel, C | 1 |
| Horger, M | 1 |
| Kum, S | 1 |
| Weisel, K | 1 |
| Fritz, J | 1 |
| Ioanoviciu, SD | 1 |
| Bier, G | 1 |
| Briani, C | 1 |
| Manara, R | 1 |
| Lessi, F | 1 |
| Citton, V | 1 |
| Zambello, R | 1 |
| Adami, F | 1 |
| Alexandrescu, S | 1 |
| Tatevian, N | 1 |
| Czerniak, BA | 1 |
| Covinsky, MH | 1 |
| Burns, NK | 1 |
| Brown, RE | 1 |
| Stewart, JM | 1 |
| Krishnamurthy, S | 1 |
| Terpos, E | 1 |
| Rahemtulla, A | 1 |
| Dimopoulos, MA | 1 |
| Ochiai, N | 1 |
| Yamada, N | 1 |
| Uchida, R | 1 |
| Fuchida, S | 1 |
| Okano, A | 1 |
| Hatsuse, M | 1 |
| Okamoto, M | 1 |
| Ashihara, E | 1 |
| Shimazaki, C | 1 |
| Sjak-Shie, NN | 1 |
| Vescio, RA | 1 |
| Berenson, JR | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
2 reviews available for thalidomide and Osteolysis
| Article | Year |
|---|---|
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2005 |
Recent advances in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chromosome | 2000 |
2 trials available for thalidomide and Osteolysis
| Article | Year |
|---|---|
Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
13 other studies available for thalidomide and Osteolysis
| Article | Year |
|---|---|
Case of lymphadenopathy with lytic bone lesions.
Topics: Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Incidental Findings; Lenalidomide; Lymph | 2017 |
A case of multiple myeloma with navicular bone involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; | 2017 |
[Digital ischemia revealing multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cryoglobulinemia; Dexamethasone; F | 2018 |
Successful treatment of acrodermatitis continua of Hallopeau with apremilast.
Topics: Acrodermatitis; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Fingers; Humans; Male; Middle A | 2019 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; | 2014 |
Osteolytic lesions in patients with relapse of diffuse large B-cell lymphoma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Middle | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; | 2014 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marro | 2016 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; | 2012 |
Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.
Topics: Biomarkers; Cell Differentiation; Cell Membrane; Cell Nucleus; Child; Child, Preschool; Cytoplasm; F | 2012 |
Fine-needle aspiration cytology of a case of HIV-associated anaplastic myeloma.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Anti-HIV Agents; Antigens, CD; Biomarkers, Tumor; | 2002 |